Drugs / A-319
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07347860 | Jan 2026 → Aug 2027 expected | rheumatoid arthritis | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06400537 | Jul 2024 → Dec 2026 expected | systemic lupus erythematosus | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 1 | NCT04056975 | Sep 2019 → Sep 2021 | B-cell non-Hodgkin lymphoma | EVIVE Biotechnology | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07371533 | Feb 2026 → Sep 2027 expected | acute lymphoblastic leukemia | Shanxi Bethune Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A-319 | “Recombinant Anti-CD19m-CD3 Antibody Injection (A-319) for Refractory/Relapsed or MRD-Positive After Induction Chemotherapy Acute B-Cell Lymphoblastic Leukemia (B-ALL) Clinical Study” NCT07371533 ↗4“Title: A Phase I, Single Centre, Open-label, Dose-escalation Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma” NCT04056975 ↗ |
| Action | Deplete | “target and kill pathogenic B cells” NCT06400537 ↗ |
| Modality | Monoclonal antibody | “Recombinant Anti-CD19m-CD3 Antibody Injection” NCT04056975 ↗ |
| Route | Intravenous | “Intravenous Infusion” NCT04056975 ↗ |
| Target | CD19 | “A-319 is a recombinant CD19xCD3 bispecific antibody that activates T cells in vivo and targets and kills pathogenic B cells.” NCT07347860 ↗ |